ANRO
Price
$11.35
Change
-$2.85 (-20.07%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
350.82M
Intraday BUY SELL Signals
NUVL
Price
$94.68
Change
-$2.35 (-2.42%)
Updated
Nov 13 closing price
Capitalization
6.88B
110 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANRO vs NUVL

Header iconANRO vs NUVL Comparison
Open Charts ANRO vs NUVLBanner chart's image
Alto Neuroscience
Price$11.35
Change-$2.85 (-20.07%)
Volume$7.18K
Capitalization350.82M
Nuvalent
Price$94.68
Change-$2.35 (-2.42%)
Volume$323.37K
Capitalization6.88B
ANRO vs NUVL Comparison Chart in %
ANRO
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ANRO vs. NUVL commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a Hold and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ANRO: $14.20 vs. NUVL: $97.03)
Brand notoriety: ANRO and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 22% vs. NUVL: 61%
Market capitalization -- ANRO: $350.82M vs. NUVL: $6.88B
ANRO [@Biotechnology] is valued at $350.82M. NUVL’s [@Biotechnology] market capitalization is $6.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both ANRO and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 3 bullish TA indicator(s).

  • ANRO’s TA Score: 4 bullish, 4 bearish.
  • NUVL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ANRO is a better buy in the short-term than NUVL.

Price Growth

ANRO (@Biotechnology) experienced а +25.78% price change this week, while NUVL (@Biotechnology) price change was +5.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($6.88B) has a higher market cap than ANRO($351M). ANRO YTD gains are higher at: 235.697 vs. NUVL (23.952). ANRO has higher annual earnings (EBITDA): -62.3M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. ANRO (148M). ANRO (0) and NUVL (0) have equivalent revenues.
ANRONUVLANRO / NUVL
Capitalization351M6.88B5%
EBITDA-62.3M-362.01M17%
Gain YTD235.69723.952984%
P/E RatioN/AN/A-
Revenue00-
Total Cash148M1.01B15%
Total Debt27.3MN/A-
TECHNICAL ANALYSIS
Technical Analysis
ANRONUVL
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ANRO
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LAAGX17.400.09
+0.52%
Lord Abbett International Growth A
VSFCX22.540.07
+0.31%
Federated Hermes Clover Small Value C
FCNAX47.62N/A
N/A
Fidelity Advisor Consumer Discret A
GSPCX15.62N/A
N/A
Goldman Sachs Large Cap Equity C
JHQDX19.79N/A
N/A
JPMorgan Hedged Equity 2 I

ANRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with BEAM. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
+5.97%
BEAM - ANRO
37%
Loosely correlated
-2.71%
IMTX - ANRO
36%
Loosely correlated
+16.10%
CLYM - ANRO
35%
Loosely correlated
+1.05%
NUVL - ANRO
34%
Loosely correlated
+0.91%
ETHZ - ANRO
34%
Loosely correlated
+0.89%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.91%
RVMD - NUVL
62%
Loosely correlated
+2.73%
XENE - NUVL
61%
Loosely correlated
-0.60%
XNCR - NUVL
60%
Loosely correlated
-3.23%
IDYA - NUVL
59%
Loosely correlated
-0.19%
CGON - NUVL
58%
Loosely correlated
+1.47%
More